Skip to main content

Gilead Sciences vs Pfizer: Strategic Comparison

Direct Answer

Pfizer is the far larger company by revenue: $62.579 billion in fiscal 2025 compared with Gilead Sciences' $29.443 billion, a gap of more than $33 billion. Gilead is more profitable on a margin basis, converting 28.9% of its FY2025 revenue into net income ($8.51 billion) versus Pfizer's 12.4% margin ($7.771 billion net income on $62.579 billion of revenue). Despite having less than half of Pfizer's revenue, Gilead's market capitalization of roughly $180 billion in September 2026 exceeded Pfizer's roughly $160 billion, reflecting investor confidence in Gilead's HIV franchise and the new Yeztugo launch against Pfizer's post-pandemic revenue decline.

In January 2026, Pfizer sold its remaining economic interest in the HIV joint venture ViiV Healthcare to Shionogi for $1.9 billion, formally exiting an HIV business it had held since ViiV's 2009 creation with GSK, the same year rival Gilead Sciences launched Yeztugo, the first twice-yearly HIV-prevention injection, and drew $20.8 billion of its revenue from HIV products. Gilead, founded in 1987 by physician-investor Michael L. Riordan, is run by Chairman and CEO Daniel O'Day, who has led it since March 2019; Pfizer, founded 138 years earlier in 1849 by chemist Charles Pfizer and his cousin Charles Erhart, is run by Chairman and CEO Albert Bourla, in the role since January 2019. For fiscal 2025, Pfizer reported $62.579 billion of revenue and $7.771 billion of net income with about 75,000 employees, more than double Gilead's $29.443 billion of revenue and 17,000 employees, yet Gilead posted the higher net income, $8.51 billion. Both companies are now pivoting toward oncology, where Gilead's Trop-2 antibody-drug conjugate Trodelvy and Pfizer's Seagen-derived ADCs such as Padcev and Adcetris compete directly for cancer patients.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldGilead Sciences, Inc.Pfizer Inc.
Latest annual revenue$29.4B (FY2025)$62.6B (FY2025)
Founded19871849
Employees17,00075,000
Market Cap$180.0B$160.3B
HeadquartersUnited StatesUnited States
Revenue / Employee$1.73M / employee$834k / employee
Valuation Multiple6.1x P/S2.6x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

Gilead Sciences, Inc. Strategic Vector

FY2025 Revenue Baseline

Gilead Sciences, Inc.'s long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward expansion of lenacapavir for hiv prevention, where yeztugo is the first twice-yearly HIV PrEP injection, and Gilead targets about $1B in 2026 sales. Concurrently, the organization focuses on navigating market pressures around intense competition in oncology adcs, addressing environments where astraZeneca's Enhertu and a new wave of next-generation ADCs from Pfizer and Daiichi Sankyo threaten to displace Trodelvy in solid tumors. By maintaining disciplined capital allocation and operational rigor, Gilead Sciences, Inc. aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $1.73M / employee

Pfizer Inc. Strategic Vector

FY2025 Revenue Baseline

Following the historic pandemic revenue windfall, Pfizer's corporate strategy centers on redeploying capital into high-growth oncology franchises and structural cost alignment. Under Chief Executive Officer Albert Bourla, Pfizer executed the landmark forty-three-billion-dollar acquisition of Seagen Inc., instantly establishing Pfizer as a global powerhouse in targeted cancer therapies. Seagen added four commercialized antibody-drug conjugates (including Padcev, Adcetris, and Tukysa) and doubled Pfizer's oncology pipeline with specialized tumor-homing molecules. Concurrently, Pfizer launched a multi-billion-dollar enterprise cost realignment program to adjust operating expenses to post-pandemic baseline demand, while launching novel vaccines including Abrysvo for respiratory syncytial virus (RSV) protection in infants and older adults.

Productivity: $834k / employee
Comparative Divergence: The two companies' most direct rivalry today runs through HIV and oncology rather than overlapping core product lines. Pfizer exited HIV altogether in January 2026, selling its stake in the GSK-controlled ViiV Healthcare joint venture to Shionogi for $1.9 billion, just as Gilead's lenacapavir franchise expanded: Yeztugo, approved in June 2025 as the first twice-yearly HIV-prevention injection, generated $232 million in the second quarter of 2026 alone. In oncology the fight is more direct: Gilead's Trop-2 ADC Trodelvy competes against Pfizer's Seagen-derived ADCs (Padcev, Adcetris, Tukysa), and in June 2026 the FDA approved Merck's Keytruda alongside Trodelvy for first-line PD-L1-positive triple-negative breast cancer, strengthening Gilead's ADC position against Pfizer's vedotin-based portfolio. Both are also chasing new pipeline assets through M&A: Gilead closed three 2026 acquisitions (Arcellx, Tubulis, Ouro Medicines) while Pfizer added Metsera in obesity and signed a 12-program Innovent oncology collaboration worth up to $10.5 billion in May 2026.

Gilead Sciences vs Pfizer Market Share

Gilead Sciences, Inc. market share
Gilead is the largest company in HIV medicines, with $20.8B in FY2025 HIV sales; Biktarvy is the most prescribed HIV treatment in the US. Its share is smaller in oncology, where cell therapy sales fell 7% in 2025.
Pfizer Inc. market share
Pfizer ranks among the top pharmaceutical companies worldwide by revenue. Its strongest positions are in pneumococcal vaccines (Prevnar), anticoagulation (Eliquis, with BMS), ATTR cardiomyopathy (Vyndaqel family) and ADC-based bladder cancer treatment (Padcev).

Quick Stats Comparison

MetricGilead Sciences, Inc.Pfizer Inc.
Revenue$29.4B (FY2025)$62.6B (FY2025)
Founded19871849
HeadquartersFoster City, CaliforniaNew York, New York
Market Cap$180.0B$160.3B
Employees17,00075,000
Revenue / Employee$1.73M / employee$834k / employee
Valuation Multiple6.1x P/S2.6x P/S

Gilead Sciences Revenue vs Pfizer Revenue — Year by Year

YearGilead Sciences, Inc.Pfizer Inc.Higher reported revenue
2025$29.4B$62.6BPfizer Inc. (approx. USD)
2024$28.8B$63.6BPfizer Inc. (approx. USD)
2023$27.1B$59.6BPfizer Inc. (approx. USD)
2022$27.3B$101.2BPfizer Inc. (approx. USD)
2021$27.3B$81.3BPfizer Inc. (approx. USD)

Business Model Breakdown

Overview: Gilead Sciences, Inc. vs Pfizer Inc.

This in-depth comparison examines Gilead Sciences, Inc. and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Gilead Sciences, Inc. on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Gilead Sciences, Inc. and Pfizer Inc. is widest.

On the headline numbers, annual revenue is $29.4B (FY2025) for Gilead Sciences, Inc. and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $180.0B and $160.3B. Both Gilead Sciences, Inc. and Pfizer Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Gilead Sciences, Inc.: Gilead Sciences is one of the largest US biotechnology companies, with about 17,000 employees and a market value near $180B in September 2026. It turned HIV into a manageable chronic disease with tenofovir-based medicines, cured most hepatitis C patients with Sovaldi and Harvoni, and supplied the first approved COVID-19 antiviral, Veklury. Today HIV accounts for roughly 71% of revenue, with oncology and liver disease making up most of the rest. The company is headquartered in Foster City, California.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.

Business Models: How Gilead Sciences, Inc. and Pfizer Inc. Make Money

Gilead Sciences, Inc. and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Gilead Sciences, Inc. and Pfizer Inc..

Gilead Sciences, Inc. business model: Gilead discovers, licenses or acquires drug candidates, takes them through clinical trials and regulatory approval, then sells them through wholesalers, pharmacies and hospitals under patent protection. Product sales were $28.9B of FY2025 revenue, with the rest coming from royalties and contract income. HIV is the profit engine: Biktarvy is a once-daily single tablet that patients typically take for years, which makes revenue recurring. Non-GAAP product gross margin was 86.4% in 2025, and Gilead spent $5.8B on R&D plus about $1.0B on acquired in-process R&D. Large acquisitions such as Pharmasset (2011), Kite (2017), Immunomedics (2020), CymaBay (2024) and Arcellx (2026) have supplied most of its new franchises.

Pfizer Inc. business model: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology. Historically recognized for blockbuster small molecules (Lipitor, Viagra, Eliquis) and pediatric vaccines (Prevnar family), Pfizer achieved unprecedented revenue scale by co-developing Comirnaty—the world's first authorized mRNA COVID-19 vaccine—with BioNTech, alongside the oral antiviral Paxlovid. The company monetizes intellectual property through global pharmaceutical distribution networks, selling to national governments, hospital purchasing organizations, and retail pharmacy chains across more than one hundred twenty countries.

Competitive Advantage: Gilead Sciences, Inc. vs Pfizer Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Gilead Sciences, Inc. stack up against those of Pfizer Inc..

Gilead Sciences, Inc. competitive advantage: Gilead's moat is three decades of antiviral chemistry and HIV clinical data. Tenofovir-based backbones, Biktarvy's single-tablet convenience and a high barrier to resistance made it the most prescribed HIV regimen in the US, and lenacapavir gave Gilead the first twice-yearly HIV prevention injection (Yeztugo, FDA approved June 2025). Its scale in HIV sales and payer contracting, plus about $10.6B of cash and marketable securities at the end of 2025, lets it fund acquisitions without depending on one deal.

Pfizer Inc. competitive advantage: Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities. Few pharmaceutical corporations in the world possess the logistical capacity to conduct concurrent Phase 3 clinical trials involving tens of thousands of patients across dozens of countries while managing ultra-low-temperature cold-chain distribution. Pfizer's Prevnar pneumococcal conjugate vaccine family has maintained multi-decade commercial dominance due to the extreme complexity of polysaccharide-protein conjugation manufacturing. Pfizer's alliance with Bristol-Myers Squibb on the anticoagulant Eliquis provides reliable, high-margin cash flow, while its commercial relationships with national healthcare authorities enable rapid global drug rollouts.

Growth Strategy: Where Gilead Sciences, Inc. and Pfizer Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how Gilead Sciences, Inc. and Pfizer Inc. each plan to expand from here.

Gilead Sciences, Inc. growth strategy: Gilead's growth plan has four parts: expand HIV prevention with Yeztugo and Descovy, defend HIV treatment with next-generation regimens such as bictegravir/lenacapavir, grow liver disease with Livdelzi, and buy into oncology and inflammation. In 2025 it acquired Interius BioTherapeutics for in vivo CAR-T. In 2026 it closed Arcellx (about $7.8B implied equity value), Tubulis ($3.15B upfront, up to $1.85B in milestones) and Ouro Medicines ($1.675B upfront, with Lakefront) to rebuild its pipeline.

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

Financial Picture: Gilead Sciences, Inc. vs Pfizer Inc.

A closer look at the financial trajectory of Gilead Sciences, Inc. and Pfizer Inc. rounds out the comparison.

Gilead Sciences, Inc.: Gilead's revenue history tracks its product cycles. Hepatitis C cures Sovaldi and Harvoni lifted revenue to $30.4B in 2016, then sales fell as patients were cured, bottoming at $22.1B in 2018. HIV growth and pandemic Veklury sales took revenue back to $27.3B in 2021, and it has since grown slowly to $28.8B in 2024 and $29.4B in 2025. Net income swings with deal accounting: it was only $480M in 2024 because of the CymaBay IPR&D charge, then recovered to $8.5B ($6.78 diluted EPS) in 2025. In Q2 2026 revenue rose 10% to $7.8B, but more than $11B of acquired IPR&D, mainly from Arcellx, produced a GAAP loss of $8.45 per share. February 2026 guidance called for $29.6B to $30.0B in 2026 product sales. Gilead Sciences, Inc. is a massive American biopharmaceutical company, commanding a market valuation typically over $80 billion.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Company-Specific SWOT Notes

Gilead Sciences, Inc.

Strength

Gilead holds a first-mover advantage in HIV with Biktarvy generating $14.3 billion in FY2025 sales.

Strength

Gilead possesses unparalleled institutional expertise in antiviral drug development, allowing it to rapidly deploy Remdesivir during the early stages of the COVID-19 pandemic.

Weakness

HIV products accounted for about 71% of FY2025 revenue ($20.8B of $29.4B).

Weakness

Because Gilead's Hepatitis C drugs (Sovaldi/Harvoni) are actual cures rather than chronic treatments, the patient pool has shrunk, permanently eroding billions in annual revenue.

Opportunity

Yeztugo is the first twice-yearly HIV PrEP injection, and Gilead targets about $1B in 2026 sales.

Threat

AstraZeneca's Enhertu and a new wave of next-generation ADCs from Pfizer and Daiichi Sankyo threaten to displace Trodelvy in solid tumors.

Pfizer Inc.

Strength

Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.

Weakness

Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.

Weakness

The impending loss of exclusivity for blockbuster drugs like Eliquis and Ibrance threatens a significant portion of Pfizer's high-margin recurring revenue by 2027.

Opportunity

The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.

Threat

Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScalePfizer Inc.$29.4B (FY2025) versus $62.6B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierPfizer Inc.Gilead Sciences, Inc. was founded in 1987; Pfizer Inc. was founded in 1849.
Verdict

Comparison Takeaway: Gilead Sciences vs Pfizer

Gilead and Pfizer sit at opposite ends of the pharmaceutical risk-reward spectrum. Gilead is concentrated and highly profitable: HIV products supplied about 71% of its $29.443 billion FY2025 revenue, led by Biktarvy's $14.3 billion in sales, and its 86.4% non-GAAP product gross margin funded roughly $12.6 billion of 2026 acquisitions (Arcellx, Tubulis, Ouro Medicines) without new debt. Pfizer is diversified but still resetting after its COVID-19 windfall: revenue fell from a $101.2 billion peak in 2022 to $62.579 billion in 2025, and the $43 billion Seagen acquisition plus the 2025 Metsera obesity deal are bets on refilling a pipeline before Eliquis, Ibrance and Xtandi lose exclusivity later this decade. On capital allocation, Pfizer carries roughly $31 billion of Seagen-related debt and pays a dividend yielding near 6%, while Gilead's $10.6 billion cash position gives it more room to keep buying smaller biotechs outright. For investors, Gilead is the higher-margin, HIV-dependent story; Pfizer is the larger, lower-margin business betting on oncology and obesity to replace lost COVID-era sales.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: Gilead Sciences vs Pfizer

Is Pfizer bigger than Gilead Sciences?

Yes, by revenue and headcount. Pfizer reported $62.579 billion of revenue in fiscal 2025, more than double Gilead Sciences' $29.443 billion, and employs about 75,000 people worldwide versus Gilead's roughly 17,000. By market value Gilead was larger, at about $180 billion versus Pfizer's roughly $160 billion in September 2026.

Which is more profitable, Gilead or Pfizer?

Gilead is more profitable on a margin basis. It converted 28.9% of its $29.443 billion FY2025 revenue into $8.51 billion of net income, compared with Pfizer's 12.4% margin on $7.771 billion of net income from $62.579 billion of revenue. Pfizer's margin is still recovering from its revenue decline off a $101.2 billion COVID-era peak in 2022.

Who runs Gilead Sciences and Pfizer?

Daniel O'Day has been Gilead's Chairman and CEO since March 2019, after running Roche's pharmaceuticals division; founder Michael L. Riordan led Gilead from 1987 to 1996. Albert Bourla has been Pfizer's CEO since January 2019 and added the Chairman title in 2020; Pfizer traces back to Charles Pfizer and Charles Erhart, who founded it in Brooklyn in 1849.

Does Pfizer still compete with Gilead in HIV?

Not as an owner anymore. Pfizer sold its remaining economic interest in the ViiV Healthcare HIV joint venture to Shionogi for $1.9 billion in January 2026, leaving GSK with a 78.3% stake. Gilead, by contrast, expanded its HIV business the same year, with its twice-yearly Yeztugo injection generating $232 million in the second quarter of 2026 alone.

Which stock is the better buy, Gilead or Pfizer?

It depends on what an investor wants. Gilead offers a higher-margin, HIV-concentrated growth story, valued at roughly $180 billion in September 2026 on $29.443 billion of FY2025 revenue, while Pfizer offers more scale and diversification at roughly $160 billion in market value on more than double Gilead's revenue, $62.579 billion, plus a dividend yielding near 6%. Neither figure accounts for future catalysts such as Gilead's lenacapavir pipeline or Pfizer's Seagen and Metsera bets.

Which company was founded first, Gilead Sciences, Inc. or Pfizer Inc.?

Pfizer Inc. was founded in 1849; Gilead Sciences, Inc. was founded in 1987.

What revenue did Gilead Sciences, Inc. and Pfizer Inc. report?

Gilead Sciences, Inc. had $29.4B (FY2025), while Pfizer Inc. had $62.6B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do Gilead Sciences, Inc. and Pfizer Inc. make money?

Gilead Sciences, Inc.: Gilead discovers, licenses or acquires drug candidates, takes them through clinical trials and regulatory approval, then sells them through wholesalers, pharmacies and hospitals under patent protection. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which is better, Gilead Sciences, Inc. or Pfizer Inc.?

There is no evidence-based single winner. Compare Gilead Sciences, Inc. and Pfizer Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Pfizer is the far larger company by revenue: $62.579 billion in fiscal 2025 compared with Gilead Sciences' $29.443 billion, a gap of more than $33 billion. Gilead is more profitable on a margin basis, converting 28.9% of its FY2025 revenue into net income ($8.51 billion) versus Pfizer's 12.4% margin ($7.771 billion net income on $62.579 billion of revenue). Despite having less than half of Pfizer's revenue, Gilead's market capitalization of roughly $180 billion in September 2026 exceeded Pfizer's roughly $160 billion, reflecting investor confidence in Gilead's HIV franchise and the new Yeztugo launch against Pfizer's post-pandemic revenue decline.

Verdict

Gilead and Pfizer sit at opposite ends of the pharmaceutical risk-reward spectrum. Gilead is concentrated and highly profitable: HIV products supplied about 71% of its $29.443 billion FY2025 revenue, led by Biktarvy's $14.3 billion in sales, and its 86.4% non-GAAP product gross margin funded roughly $12.6 billion of 2026 acquisitions (Arcellx, Tubulis, Ouro Medicines) without new debt. Pfizer is diversified but still resetting after its COVID-19 windfall: revenue fell from a $101.2 billion peak in 2022 to $62.579 billion in 2025, and the $43 billion Seagen acquisition plus the 2025 Metsera obesity deal are bets on refilling a pipeline before Eliquis, Ibrance and Xtandi lose exclusivity later this decade. On capital allocation, Pfizer carries roughly $31 billion of Seagen-related debt and pays a dividend yielding near 6%, while Gilead's $10.6 billion cash position gives it more room to keep buying smaller biotechs outright. For investors, Gilead is the higher-margin, HIV-dependent story; Pfizer is the larger, lower-margin business betting on oncology and obesity to replace lost COVID-era sales.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Gilead Sciences, Inc. vs Pfizer Inc. Comparison. from https://corpdigest.com/compare/gilead-sciences-vs-pfizer

MLA Format

CorpDigest. "Gilead Sciences, Inc. vs Pfizer Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/gilead-sciences-vs-pfizer.

Chicago Format

CorpDigest. "Gilead Sciences, Inc. vs Pfizer Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/gilead-sciences-vs-pfizer.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.